AURORA 1
2021
Voclosporin for Lupus Nephritis (AURORA 1)
In 357 patients with active lupus nephritis, adding voclosporin to MMF and low-dose steroids increased complete renal response at week 52 compared with placebo.
Result
Efficacy: Complete renal response at week 52OR 2.65 (95% CI 1.64-4.27) · P < 0.0001
Below 1 favours placebo, above 1 favours voclosporin to MMF and low-dose steroids.
- Absolute difference
- 18 points
- NNT
- 6
Absolute difference and NNT are derived from the event rates.
- Subtopic
- Lupus nephritis
- Design
- Phase 3 double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Rovin BH, et al. Lancet. 2021;397(10289):2070-2080.doi 10.1016/S0140-6736(21)00578-X
Discussion & critique
Led to FDA approval of voclosporin; AURORA 2 showed the benefit sustained over 2 years.